88054-14-2

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazole,5-methylis used as a key intermediate in the synthesis of pharmaceuticals for its unique chemical properties and reactivity. It contributes to the development of new drugs and medications, enhancing their efficacy and therapeutic potential.
Used in Agrochemical Industry:
In the agrochemical sector, 1H-Pyrazole,5-methylserves as an essential intermediate in the production of agrochemicals. Its unique chemical structure allows for the creation of compounds with specific pesticidal, herbicidal, or fungicidal properties, contributing to improved crop protection and yield.
Used in Research and Development:
1H-Pyrazole,5-methylis utilized in research and development within the pharmaceutical and agricultural industries. Its unique chemical properties and reactivity make it a valuable tool for exploring new chemical reactions, synthesizing novel compounds, and advancing scientific understanding in these fields.
Overall, 1H-Pyrazole,5-methylis a versatile and important chemical compound with a wide range of applications in various industries, particularly in the synthesis of pharmaceuticals, agrochemicals, and organic compounds. Its unique chemical properties and reactivity make it a valuable asset in the development of new and improved products in these sectors.

Upstream product

• 120-94-5 1-Methylpyrrolidine 
• 367-57-7 1,1,1-Trifluoro-2,4-pentanedione 
• 27246-81-7 3-bromophenylhydrazine hydrochloride 

Downstream Products

• 220462-02-2 2-chloro-4-(3-methylpyrazol-1-yl)benzoic acid methyl ester 
• 1101099-34-6 N-{2-[3⁽⁵⁾-methyl-1H-pyrazol-1-yl]ethyl}ethane-1,2-diamine 
• 62821-90-3 2-[3(5)-methyl-1H-pyrazol-1-yl]ethanamine 
• 1004096-15-4 1-(difluoromethyl)-5-methyl-1H-pyrazole 
• 1123828-07-8 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole 
• 701212-65-9 1-(4-benzoylpiperazin-1-yl)-2-(4-methoxy-7-(5-methyl-1H-pyrazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 15802-75-2 3-iodo-2-methyl-1H-pyrazole 
• 13788-99-3 5-methyl-1-(4-nitrophenyl)-1H-pyrazole 
• 371118-71-7 methyl 3-(3-methyl-1H-pyrazol-1-yl)propionate 

Relevant academic research and scientific papers

TRICYCLIC PYRIDINE N-OXIDES VASOPRESSIN AGONISTS

The present invention provides compounds of general formula (I) as well as methods and pharmaceutical compositions utilizing these compounds for the inducement of temporary delay of urination or the treatment of disorders which may be remedied or alleviated by vasopressin agonist activity, including diabetes, insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders.

Tricyclic pyrido vasopressin agonists

The present invention provides compounds of the general formula: wherein W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilizing these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.

Tricyclic pyridine N-oxides vasopressin agonists

The present invention provides compounds of the general formula: as well as methods and pharmaceutical compositions utilizing these compounds for the inducement of temporary delay of urination or the treatment of disorders which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders.

Nitrogen containing heteroaromatics as factor Xa inhibitors

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(=NH)NH2, which are useful as inhibitors of factor Xa.

Tricyclic vasopressin agonists

The present invention provides compounds of the general formula: wherein W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilizing these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.